Sivec Biotechnologies
Fort Collins
About Sivec Biotechnologies
SiVEC Biotechnologies delivery platform uses non-pathogenic bacteria for targeted intracellular delivery of nucleic acid drugs and vaccines to mucosal epithelial cells. They concentrate on developing a drug delivery platform that is characterized as nonpathogenic bacteria that constitutively generate therapeutic nucleic acids and gene editing components for targeted intracellular delivery to mucosal epithelial cells.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $3.5M
- Funding stage: Seed
- Last round: Seed (Sep 2025)
- Website: sivecbiotechnologies.com
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/sivec-biotechnologies-13315 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.